Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Turkiye

被引:0
作者
Buyukyanbolu, Ecem [1 ,2 ]
Gill, Christian M. [2 ]
Genc, Leyla [1 ]
Karakus, Mehmet [3 ]
Comert, Fusun [4 ]
Otlu, Baris [5 ]
Aktas, Elif [1 ]
Nicolau, David P. [2 ]
机构
[1] Univ Hlth Sci, Hamidiye Etfal Training & Res Hosp, Dept Med Microbiol, Istanbul, Turkiye
[2] Hartford Hosp, Ctr Antiinfect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA
[3] Univ Hlth Sci, Dept Med Microbiol, Istanbul, Turkiye
[4] Bulent Ecevit Univ, Fac Med, Dept Med Microbiol, Zonguldak, Turkiye
[5] Inonu Univ, Fac Med, Dept Med Microbiol, Malatya, Turkiye
关键词
P; aeruginosa; Dose optimization; Cephalosporin; PK/PD; Carbapenem resistance; IN-VIVO EFFICACY; DOSING INTERVALS; THIGH-INFECTION; BETA-LACTAM; INFUSION; PHARMACODYNAMICS; PNEUMONITIS; MEROPENEM; IMIPENEM; OUTCOMES;
D O I
10.1007/s10096-024-04990-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Although CRPA may test susceptible to other beta-lactams such as ceftazidime (CAZ), cefepime (FEP), and piperacillin/tazobactam (TZP), reduced potency has been observed. We assessed the adequacy of EUCAST Susceptible (S) or Susceptible Increased Exposure (SIE)/(I) doses for CAZ, FEP, and TZP against CRPA clinical isolates. Methods CRPA isolates were collected from patients at three Turkish hospitals. CAZ, FEP, and TZP MICs were determined using broth microdilution. Monte Carlo simulations were performed to determine the probability of target attainment (PTA) for a free time above the MIC (fT > MIC) targets for various doses of each agent against isolates defined as susceptible. fT > MIC targets were 70% for CAZ or FEP and 50% for TZP. Cumulative fraction of response (CFR) was calculated. Optimal PTA and CFR was 90% target achievement. Results The percentages of isolates SIE/I to CAZ, FEP, and TZP were 49,8%, 47%, and 31,8% respectively. Reduced potency was noted with 54,1% of CAZ-S isolates having MICs of 4 or 8 mg/L. Of the FEP and TZP-S isolates, MICs at the breakpoint (8 and 16 mg/L, respectively) were the mode with 45,2 and 53,9% of isolates for each, respectively. At an MIC of 8 mg/L for CAZ, the EUCAST standard dose was insufficient (CFR of 85%). 3 h infusions of EUCAST SIE doses were required for 90% PTA at MIC of 8 mg/L and an optimized CFR of 100%. For FEP, the SIE dose of 2 g q8h 0.5 h infusion of was effective (CFR 96%), utilization of an extended 3 h infusion further optimized the PTA at 8 mg/L (CFR 99%). For TZP, the standard dose of 4.5 q6h administered as a 0.5 h infusion was inadequate (CFR 86%). A standard TZP dose with an extended infusion (4.5 g q8h over 4 h) and the SIE dose 4.5 g q6h 3 h infusion resulted in CFRs > 95%. Conclusion These data support the EUCAST SIE breakpoints for FEP and TZP. To optimize PTA at the SIE breakpoint for CAZ, prolonged infusion is required.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 50 条
  • [21] Molecular epidemiological characteristics of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in southeast Shanxi, China
    Bai, Yang
    Gong, Yan-e
    Shen, Fangfang
    Li, Hui
    Cheng, Yan
    Guo, Jinying
    Liu, Guangming
    Ji, Ai -fang
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 36 : 301 - 306
  • [22] In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates
    Wilhelm, Camila M.
    Nunes, Luciana de S.
    Martins, Andreza F.
    Barth, Afonso L.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 92 (02) : 152 - 154
  • [23] Emerging Carbapenem-Resistant Pseudomonas aeruginosa Isolates Carrying bla(IMP) Among Burn Patients in Isfahan, Iran
    Radan, Mohsen
    Moniri, Rezvan
    Khorshidi, Ahmad
    Gilasi, Hamidreza
    Norouzi, Zohreh
    Beigi, Fahimeh
    Goli, Yasaman Dasteh
    ARCHIVES OF TRAUMA RESEARCH, 2016, 5 (03)
  • [24] Risk Factors for Carbapenem-resistant Pseudomonas aeruginosa Infection in Children
    Li, Lu
    Huang, Yanfeng
    Tang, Qiqin
    Zheng, Yuqiang
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (08) : 642 - 647
  • [25] INCIDENCE OF CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA IN DIABETES AND CANCER PATIENTS
    Varaiya, A.
    Kulkarni, M.
    Bhalekar, P.
    Dogra, J.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 26 (03) : 238 - 240
  • [26] Quorum Sensing and Genetic Lineages in Carbapenem-Resistant Pseudomonas aeruginosa
    Shafigh, Maryam
    Pournajaf, Abazar
    Amoli, Rabeeh Izadi
    Yahyapour, Yousef
    Kaboosi, Hami
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2024, 17 (10)
  • [27] Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan
    Yano, Hirokazu
    Hayashi, Wataru
    Kawakami, Sayoko
    Aoki, Sadao
    Anzai, Eiko
    Zuo, Hui
    Kitamura, Norikazu
    Hirabayashi, Aki
    Kajihara, Toshiki
    Kayama, Shizuo
    Sugawara, Yo
    Yahara, Koji
    Sugai, Motoyuki
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (05)
  • [28] Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
    Vivo, Amanda
    Fitzpatrick, Margaret A.
    Suda, Katie J.
    Jones, Makoto M.
    Perencevich, Eli N.
    Rubin, Michael A.
    Ramanathan, Swetha
    Wilson, Geneva M.
    Evans, Martin E.
    Evans, Charlesnika T.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [29] Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
    Amanda Vivo
    Margaret A. Fitzpatrick
    Katie J. Suda
    Makoto M. Jones
    Eli N. Perencevich
    Michael A. Rubin
    Swetha Ramanathan
    Geneva M. Wilson
    Martin E. Evans
    Charlesnika T. Evans
    BMC Infectious Diseases, 22
  • [30] In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains
    Erdem, I
    Kucukercan, M
    Ceran, N
    CHEMOTHERAPY, 2003, 49 (06) : 294 - 297